Referências bibliográficas

• [1] (1) Fuster V, Sweeny JM. Aspirin: A Historical and Contemporary Therapeutic Overview. Circulation. 2011;123(7): 768–778

• [2] (2) Capodanno, Davide, Dominick J. Angiolillo. "Aspirin for primary cardiovascular risk prevention and beyond in diabetes mellitus." Circulation. 2016;134(20): 1579–1594.

• [3] (3) Belanger C, Braunwald E, Buring J E. et al, ‘’Findings from the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. jan 1988;318262- 264

• [4] (4) Collaboration AT. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J. 2002;324(7329):71-86

• [5] (5) Berg A. O, Allan J, Frame P S. et al. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med. 2002; 136(2): 157.

• [6] (6) Collins R, Peto R, Hennekens C. et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. The Lancet. 2009; 373(9678):1849-

• [7] (7) Stratmann B, Tschoepe D. Pathobiology and cell interactions of platelets in diabetes. Diab Vasc Dis Res. 2005;2(1): 16–23.

• [8] (8) Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005;54(8): 2430–2435.

• [9] (9) Vinik AI, Erbas T, Park TS, et al. Platelet dysfunction in type 2 diabetes. Diabetes Care. 2001;24(8): 1476–1485.

• [10] (10) Ferroni P, Basili S, Falco A, et al. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost. 2004;2(8):1282–1291.

• [11] (11) Vaidyula VR, Boden G, Rao AK. Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects. Platelets. 2006;17:577–585.

• [12] (12) Keating FK, Sobel BE, Schneider DJ. Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. Am J Cardiol. 2003;92: 1362–1365

• [13] (13) Assert R, Scherk G, Bumbure A, et al. Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. Diabetologia. 2001;44:188–195.

• [14] (14) Ishida M, Ishida T, Ono N, et al. Effects of insulin on calcium metabolism and platelet aggregation. Hypertension. 1996;28:209–212.

• [15] (15) Betteridge DJ, El Tahir KE, Reckless JP, et al. Platelets from diabetic subjects show diminished sensitivity to prostacyclin. Eur J Clin Invest. 1982;12:395–398.

• [16] (16) Anfossi G, Mularoni EM, Burzacca S, et al. Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabetes Care. 1998;21:121–126.

• [17] (17) Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134-41.

• [18] (18) Ferreiro JL, Angiolillo DJ. Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome. Circulation. 2011;123(7):798-813.

• [19] (19) Collins R. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. The Lancet. 2009;373(9678):1849-1860

• [20] (20) Saito Y, Okada S, Ogawa H, et al. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial. Circulation. 2016;135(7): 659–670

• [21] (21) Collaboration AT. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. The Lancet. 2009;373(9678): 1849–1860.

• [22] (22) Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979.

• [23] (23) Rothwell PM, Cook NR, Gaziano JM, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. The Lancet. 2018;392(10145): 387–399.

• [24] (24) Aspirin for primary prevention of cardiovascular disease? Drug Ther Bull. 2009;47:122–125.

• [25] (25) Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295:306 –313.

• [26] (26) Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 1996;348:1413–1416.

• [27] (27) Xie M, Shan Z, Zhang Y, et al. Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status. PLoS One. 2014;9:e90286.

• [28] (28) De Berardis G, Sacco M, Strippoli GF, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ. 2009;339:b4531.

• [29] (29) Pignone M, Williams CD. Aspirin for primary prevention of cardiovascular disease in diabetes mellitus. Nat Rev Endocrinol. 2010;6:619-28.

• [30] (30) The ASCEND Study Collaborative Group. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med [Internet]. 2018 ago [citado 2018 set. 15]. Disponível em: https://www.nejm.org/doi/full/10.1056/NEJMoa1804988#article_citing_articles [Epub ahead of print]